4BASEBIO PLC (88Q.DE) Stock Price, Forecast & Analysis
Europe - FRA:88Q - GB00BMCLYF79 - Common Stock
88Q.DE Key Statistics, Chart & Performance
The current stock price of 88Q.DE is 8.2 EUR. In the past month the price decreased by -18.81%. In the past year, price decreased by -52.6%.
88Q.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 71.36 | 47.19B | ||
| 1AE.DE | ARGENX SE | 72.42 | 47.89B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.12B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.07B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.00B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.82B | ||
| 5CV.DE | CUREVAC NV | 5.3 | 1.04B | ||
| NANO.PA | NANOBIOTIX | N/A | 871.73M | ||
| PHIL.MI | PHILOGEN SPA | 20.7 | 690.06M | ||
| IVA.PA | INVENTIVA SA | N/A | 487.90M | ||
| FYB.DE | FORMYCON AG | N/A | 373.72M | ||
| VLA.PA | VALNEVA SE | N/A | 342.47M |
Related stock screener links
About 88Q.DE
Company Profile
4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The firm offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. The company utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The firm offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Company Info
4BASEBIO PLC
25 Norman Way, Over
CAMBRIDGE GB
Employees: 0
Phone: 441223967943
4BASEBIO PLC / 88Q.DE FAQ
Can you describe the business of 4BASEBIO PLC?
4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The firm offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. The company utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The firm offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
What is the current price of 88Q stock?
The current stock price of 88Q.DE is 8.2 EUR. The price decreased by -0.61% in the last trading session.
Does 4BASEBIO PLC pay dividends?
88Q.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of 88Q stock?
88Q.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting 88Q stock to perform?
9 analysts have analysed 88Q.DE and the average price target is 20.21 EUR. This implies a price increase of 146.48% is expected in the next year compared to the current price of 8.2.
88Q.DE Technical Analysis
88Q.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 88Q.DE. While 88Q.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
88Q.DE Financial Highlights
Over the last trailing twelve months 88Q.DE reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS decreased by -26.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.08% | ||
| ROE | -75.9% | ||
| Debt/Equity | 0.81 |
88Q.DE Forecast & Estimates
9 analysts have analysed 88Q.DE and the average price target is 20.21 EUR. This implies a price increase of 146.48% is expected in the next year compared to the current price of 8.2.
For the next year, analysts expect an EPS growth of -34.32% and a revenue growth 50% for 88Q.DE